ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last241 to 260 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Prevalence of Anxiety Episodes (Crohn's Disease)262 of 7,557

892 of 30,228

0.5 points

0.1 to 1.0

37,785NCT03836612

Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease

People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Number of People With Depressive Disorder in People With and Without Crohn's Disease1,322 of 7,557

3,911 of 30,228

4.6 points

3.6 to 5.5

37,785NCT03836612

Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease

Brief Clinician Education vs Clinical Decision Support Nudges and Brief Clinician Education: deaths from any cause511 of 18,709

469 of 18,425

0.2 points

-0.1 to 0.5

37,134NCT04289753

Behavioral Economics Applications to Geriatrics Leveraging EHRs R33 Trial

Cases vs Controls: Number of Participants With Recurrent Depressive Disorder1,093 of 7,224

4,305 of 28,880

0.2 points

-0.7 to 1.2

36,104NCT04953338

Mental Health Associations With Vitiligo

Cases vs Controls: Number of Participants With Anxiety Disorder569 of 7,224

2,031 of 28,880

0.8 points

0.2 to 1.5

36,104NCT04953338

Mental Health Associations With Vitiligo

Cases vs Controls: Number of Participants With Depressive Episodes1,018 of 7,224

4,007 of 28,880

0.2 points

-0.7 to 1.1

36,104NCT04953338

Mental Health Associations With Vitiligo

NuvaRing vs Combined Oral Contraceptives (COC): serious adverse events577 of 17,084

751 of 17,016

-1.0 points

-1.4 to -0.6

34,100NCT00524771

Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC)

Direct Acting Antivirals vs Comparison: deaths from any cause77 of 15,524

2,186 of 18,284

-11.5 points

-11.9 to -11.0

33,808NCT03423641

An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

Male Cases vs Male Controls: Number of New Onset Skin Cancers in the Male Sex Subgroup55 of 6,823

383 of 26,936

-0.6 points

-0.9 to -0.3

33,759NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Cases vs Controls: Number of New Onset Skin Cancers in the <45 Age Subgroup11 of 6,711

72 of 26,789

-0.1 points

-0.2 to 0.0

33,500NCT04969419

Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo

Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants With Non-fatal SAEs2 of 16,549

0 of 16,544

0.0 points

-0.0 to 0.0

33,093NCT04137887

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants With Hospitalizations Due to Cardiovascular or Respiratory Diseases257 of 16,549

272 of 16,544

-0.1 points

-0.4 to 0.2

33,093NCT04137887

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Group1: QIV-HD vs Group 2: QIV-SD: deaths from any cause102 of 16,549

92 of 16,544

0.1 points

-0.1 to 0.2

33,093NCT04137887

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

Group1: QIV-HD vs Group 2: QIV-SD: serious adverse events109 of 16,549

98 of 16,544

0.1 points

-0.1 to 0.2

33,093NCT04137887

Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older

AZD1222 vs Placebo: deaths from any cause62 of 21,587

33 of 10,793

-0.0 points

-0.2 to 0.1

32,380NCT04516746

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

AZD1222 vs Placebo: serious adverse events1,039 of 21,587

467 of 10,793

0.5 points

-0.0 to 1.0

32,380NCT04516746

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Cervarix Pooled Group vs Engerix-B Pooled Group: Number of Subjects With New Onset of Autoimmune Diseases (NOADs), Retrieved From Care Register for Social Welfare and Health Care (HILMO)149 of 14,837

180 of 17,338

-0.0 points

-0.3 to 0.2

32,175NCT00534638

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Cervarix Pooled Group vs Engerix-B Pooled Group: Number of Subjects Reporting SAEs Assessed by the Investigator as Possibly Related to Vaccination25 of 14,837

30 of 17,338

-0.0 points

-0.1 to 0.1

32,175NCT00534638

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Cervarix Pooled Group vs Engerix-B Pooled Group: serious adverse events188 of 14,837

152 of 17,338

0.4 points

0.2 to 0.6

32,175NCT00534638

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Users of DRSP vs Users of LNG: Number of Participants With Venous Thromboembolism (VTE)26 of 16,534

25 of 15,428

-0.0 points

-0.1 to 0.1

31,962NCT00302848

European Active Surveillance Study (EURAS)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=13

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03836612-970d1725",
        "title": "People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Prevalence of Anxiety Episodes (Crohn's Disease)",
        "summary": "262 of 7557 against 892 of 30228; risk difference 0.5 points, 95% interval 0.1 to 1.0; NCT03836612, Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease",
        "record": "/library/comparisons/NCT03836612-970d1725",
        "nct_id": "NCT03836612",
        "kind": "outcome",
        "participants": 37785,
        "risk_difference": {
          "value": 0.005160778086542275,
          "lower": 0.0007976147979284988,
          "upper": 0.009902806659750787
        },
        "group_1": "262 of 7,557",
        "group_2": "892 of 30,228",
        "difference": "0.5 points",
        "interval": "0.1 to 1.0",
        "trial_title": "Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease"
      },
      {
        "id": "NCT03836612-e6868fdd",
        "title": "People With Crohn's Disease (Cases) vs People Without Crohn's Disease (Controls): Number of People With Depressive Disorder in People With and Without Crohn's Disease",
        "summary": "1322 of 7557 against 3911 of 30228; risk difference 4.6 points, 95% interval 3.6 to 5.5; NCT03836612, Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease",
        "record": "/library/comparisons/NCT03836612-e6868fdd",
        "nct_id": "NCT03836612",
        "kind": "outcome",
        "participants": 37785,
        "risk_difference": {
          "value": 0.04555379118697897,
          "lower": 0.036321689525995904,
          "upper": 0.05504996020503928
        },
        "group_1": "1,322 of 7,557",
        "group_2": "3,911 of 30,228",
        "difference": "4.6 points",
        "interval": "3.6 to 5.5",
        "trial_title": "Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=14",
  "request_id": "8xak5TF3ryX5MN6E"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?